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phan could further augment the vascular actions of bradykinin in patients with CHF on
chronic ACE inhibitor therapy.
Methods 10 patients with CHF on chronic ACE inhibitor therapy received an intrabrachial
infusion of thiorphan (30 nmol/min) or saline placebo for 3 hours in a randomised, double
blind, cross over trial. Thiorphan or placebo was coinfused with Lys-des-Arg9-bradykinin
(B1 kinin receptor agonist; 1 - 10 nmol/min), bradykinin (B2 kinin receptor agonist; 30 -
300 pmol/min), atrial natriuretic peptide (10 -100 pmol/min) and sodium nitroprusside (2 -
8 mcg/min) in random order. Bilateral forearm blood flow (FBF) was recorded using strain
gauge plethysmography and plasma t-PA antigen determined using ELISA.
Results There were no changes in heart rate, blood pressure or noninfused FBF or t-PA
release during thiorphan or placebo infusion. Bradykinin, atrial natriuretic peptide and
sodium nitroprusside caused dose-dependent increases in infused FBF in all studies
(p<0.001). There were no significant changes in FBF during Lys-des-Arg9-bradykinin
infusion. Bradykinin but not Lys-des-Arg9-bradykinin or atrial natriuretic peptide caused a
dose dependent increase in t-PA antigen and estimated t-PA antigen release in all stud-
ies (p<0.001). Compared to placebo, thiorphan augmented the increase in infused FBF,
t-PA antigen and estimated t-PA antigen release (p<0.001, p=0.076, p<0.005 respec-
tively) to bradykinin but not atrial natriuretic peptide or sodium nitroprusside.
Conclusion In the presence of chronic systemic ACE inhibition, local NEP inhibition
potentiates bradykinin mediated vasodilatation and endothelial t-PA release. Given these
potential anti-ischaemic benefits, our findings support the hypothesis that combined
ACE/NEP inhibition may afford greater cardiovascular protection than ACE inhibition
alone.
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Background: Following a myocardial infarction (MI), treatment with angiotensin convert-
ing enzyme inhibitors reduces mortality and morbidity in patients with left ventricular dys-
function (LVD). However, long-term benefits remain unknown. We conducted a follow-up
study on the long-term effects of trandolapril use post-MI in patients with LVD.
Methods: In the Trandolapril Cardiac Evaluation (TRACE) study, 1,749 patients with LVD
(ejection fraction <35%) were randomized to trandolapril (n = 876) or placebo (n = 873) 3-
7 days post-MI. The study began in 1990 and closed in 1994; on–treatment follow-up
ranged from 2-4 years. National registries were used to track all deaths and hospitaliza-
tions until the end of 2002. We analyzed mortality with Cox proportional hazard models
and hospitalization with Poisson regression models (models adjusted for observation
time).
Results: Over 10-12 years of follow-up, a total of 1,281 deaths and 9,192 hospitalizations
were registered. Compared with the placebo group, the trandolapril group had a signifi-
cantly reduced risk of all-cause mortality and significantly reduced rates of all–cause
hospitalizations and congestive heart failure (CHF) hospitalizations (table).
Conclusion: In patients with LVD, use of trandolapril shortly after an MI for 2-4 years has
long-term benefits. Trandolapril reduces mortality and hospitalization rates for at least 10-
12 years. Further follow-up is required to determine the limit of these beneficial effects.
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Background: The combination of an angiotensin-II receptor blocker (ARB) with an ACE
inhibitor (ACEi) provides benefits on clinical events and LV remodelling in patients with
congestive heart failure (CHF). The primary objective of this study was to investigate the
effects of Irbesartan versus placebo on submaximal exercise duration in patients with
CHF. The secondary objective was to assess the impact of such treatment on catechola-
mines and angiotensin-II (A-II) levels at rest, at 6 minutes, and at peak exercise during a
submaximal exercise test. Methods: Thirty-three patients with NYHA II or III CHF aged
56±12 years (mean±SD), LVEF 25.5±7.2%, and with exercise limited by dyspnea were
prospectively studied. Patients were blindly randomized to receive either Irbesartan 150
mg o.d. (n=22) or a placebo (n=11) for 6 months (m) in addition to optimal dose of ACEi
and beta-blockers. Maximal exercise capacity was evaluated using a Ramp protocol.
Submaximal exercise duration was assessed using a constant load protocol prescribed
at the level of the anaerobic threshold. Gas exchange was measured continuously during
both protocols. Results: (See Table). Conclusions: Dual A-II suppression with Irbesartan
and ACEi therapy improves submaximal exercise time by 23% without significant
changes in neurohumoral response at rest or during stress.
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Background: Statins have pleiotropic effects such as anti-inflammatory and vascular
protective effects, which would be beneficial for patients with chronic heart failure (CHF).
We sought to investigate the long-term effect of statins on exercise tolerance, cardiac
function and prognosis in patients with ischemic CHF.
Methods: We prospectively followed-up 66 consecutive ischemic CHF outpatients with
radionuclide left ventricular ejection fraction (RI-LVEF) < 40% for three years. At the
entry, we measured six minute walk distance (6MWD), left ventricular end-diastolic
dimension (LVDd) in echocardiography, RI-LVEF and plasma concentration of atrial natri-
uretic peptide (ANP), and thereafter these measurements were repeated at least every
year.
Results: There were no significant differences in age, gender, NYHA class, 6MWD,
LVDd or RI-LVEF at the entry between patients with (n=27) and without statins (n=39).
After the follow-up period of 2.8±0.5 years, patients with statins had a significant increase
in 6MWD and RI-LVEF and a decrease in LVDd and plasma level of ANP, while there
were no significant changes in these parameters in patients without statins. Furthermore,
during the follow-up period, the cardiac events were significantly (p=0.004) infrequently
observed in patients with (0%) than without statins (26%).
Conclusion: Long-term statin treatment might improve exercise tolerance and cardiac
function, resulting in an improvement in clinical outcome in patients with ischemic CHF.
Event Number of 
Events
Risk/Rate 
Ratio*
95% CI p Value
All-cause death
Overall 1990-2002 1,281 0.89† 0.80-0.99 0.04
Trial period 1990-1994 675 0.78† 0.67-0.91 0.001
After trial 1994-2002 606 1.03† 0.88-1.21 0.68
All-cause hospitalization
Overall 1990-2002 9192 0.92‡ 0.88-0.96 <0.001
Trial period 1990-1994 4599 0.92‡ 0.87-0.98 <0.005
After trial 1994-2002 4593 0.92‡ 0.87-0.98 0.005
CHF hospitalization
Overall 1990-2002 1,628 0.85‡ 0.77-0.93 <0.001
Trial period 1990-1994 817 0.76‡ 0.67-0.88 <0.001
After trial 1994-2002 811 0.94‡ 0.82-1.08 0.82
*Risk/rate ratio <1.0 favors trandolapril over placebo
†Risk ratio; ‡Rate ratio; CI, conficence interval
VO2 Peak 
ml/kg/min
Duration 
Max 
(sec)
Duration 
Submax 
(sec)
A-II
(pg/ml)
(6 m)
Bsl 6 m Bsl 6 m Bsl 6 m Rest Peak Ex
Irbe 
(n=22)
19.1±4.9 19.6
±4.3
554±127 578±
123
1043±507 1360*
±725
286±211 262±180
Placebo 
(n=11)
21.3±6.4 20.5
±6.6
630±140 647±
15
1581±664 1697
±743
239±118 310±272
Mean±SD; Irbe=Irbesartan: Bsl=baseline; Ex=exercise; *p=0.018 vs Bsl by Wilcoxon.
With statins Without statins p Value
at entry follow-up at entry follow-up (ANOVA)
6MWD (m) 363±73 392±68 374±88 363±100 0.008
RI-LVEF (%) 28.9±6.6 35.5±10.9 30.3±7.6 31.4±11.5 0.012
LVDd (mm) 58.3±5.4 56.4±6.7 60.5±7.4 61.6±7.7 0.02
ANP (pg/ml) 55.9±51.3 33.3±24.7 62.8±53.2 80.3±100.5 0.04
